Regeneron Announced Phase 4 REMODEL Trial Results Showing Dupixent Improved Esophageal Function Vs Placebo In Adults With Eosinophilic Esophagitis At 24 Weeks

Benzinga Newsdesk www.benzinga.com Positive 95.2%

Neg 0% Neu 0% Pos 95.2%

Comments

No comments yet. Be the first!